In the course of thinking about metrics, I keep coming across cases of over-promoted research. An early case was “Why honey isn’t a wonder cough cure: more academic spin“. More recently, I noticed these examples.
“Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease".(Spoiler -very little), published in the Journal of the American Medical Association. ”
and ” Primary Prevention of Cardiovascular Disease with a Mediterranean Diet” , in the New England Journal of Medicine (which had second highest altmetric score in 2013)
and "Sleep Drives Metabolite Clearance from the Adult Brain", published in Science
In all these cases, misleading press releases were issued by the journals themselves and by the universities. These were copied out by hard-pressed journalists and made headlines that were certainly not merited by the work. In the last three cases, hyped up tweets came from the journals. The responsibility for this hype must eventually rest with the authors. The last two papers came second and fourth in the list of highest altmetric scores for 2013
Here are to two more very recent examples. It seems that every time I check a highly tweeted paper, it turns out that it is very second rate. Both papers involve fMRI imaging, and since the infamous dead salmon paper, I’ve been a bit sceptical about them. But that is irrelevant to what follows.
Boost your memory with electricity
That was a popular headline at the end of August. It referred to a paper in Science magazine:
“Targeted enhancement of cortical-hippocampal brain networks and associative memory” (Wang, JX et al, Science, 29 August, 2014)
This study was promoted by the Northwestern University "Electric current to brain boosts memory". And Science tweeted along the same lines.
Science‘s link did not lead to the paper, but rather to a puff piece, "Rebooting memory with magnets". Again all the emphasis was on memory, with the usual entirely speculative stuff about helping Alzheimer’s disease. But the paper itself was behind Science‘s paywall. You couldn’t read it unless your employer subscribed to Science.
All the publicity led to much retweeting and a big altmetrics score. Given that the paper was not open access, it’s likely that most of the retweeters had not actually read the paper.
When you read the paper, you found that is mostly not about memory at all. It was mostly about fMRI. In fact the only reference to memory was in a subsection of Figure 4. This is the evidence.
That looks desperately unconvincing to me. The test of significance gives P = 0.043. In an underpowered study like this, the chance of this being a false discovery is probably at least 50%. A result like this means, at most, "worth another look". It does not begin to justify all the hype that surrounded the paper. The journal, the university’s PR department, and ultimately the authors, must bear the responsibility for the unjustified claims.
Science does not allow online comments following the paper, but there are now plenty of sites that do. NHS Choices did a fairly good job of putting the paper into perspective, though they failed to notice the statistical weakness. A commenter on PubPeer noted that Science had recently announced that it would tighten statistical standards. In this case, they failed. The age of post-publication peer review is already reaching maturity
Boost your memory with cocoa
"Enhancing dentate gyrus function with dietary flavanols improves cognition in older adults. Brickman et al., Nat Neurosci. 2014. doi: 10.1038/nn.3850.".
The journal helpfully lists no fewer that 89 news items related to this study. Mostly they were something like “Drinking cocoa could improve your memory” (Kat Lay, in The Times). Only a handful of the 89 reports spotted the many problems.
A puff piece from Columbia University’s PR department quoted the senior author, Dr Small, making the dramatic claim that
“If a participant had the memory of a typical 60-year-old at the beginning of the study, after three months that person on average had the memory of a typical 30- or 40-year-old.”
Like anything to do with diet, the paper immediately got circulated on Twitter. No doubt most of the people who retweeted the message had not read the (paywalled) paper. The links almost all led to inaccurate press accounts, not to the paper itself.
But some people actually read the paywalled paper and post-publication review soon kicked in. Pubmed Commons is a good site for that, because Pubmed is where a lot of people go for references. Hilda Bastian kicked off the comments there (her comment was picked out by Retraction Watch). Her conclusion was this.
"It’s good to see claims about dietary supplements tested. However, the results here rely on a chain of yet-to-be-validated assumptions that are still weakly supported at each point. In my opinion, the immodest title of this paper is not supported by its contents."
NHS Choices spotted most of the problems too, in "A mug of cocoa is not a cure for memory problems". And so did Ian Musgrave of the University of Adelaide who wrote "Most Disappointing Headline Ever (No, Chocolate Will Not Improve Your Memory)",
Here are some of the many problems.
- The paper was not about cocoa. Drinks containing 900 mg cocoa flavanols (as much as in about 25 chocolate bars) and 138 mg of (−)-epicatechin were compared with much lower amounts of these compounds
- The abstract, all that most people could read, said that subjects were given "high or low cocoa–containing diet for 3 months". Bit it wasn’t a test of cocoa: it was a test of a dietary "supplement".
- The sample was small (37ppeople altogether, split between four groups), and therefore under-powered for detection of the small effect that was expected (and observed)
- The authors declared the result to be "significant" but you had to hunt through the paper to discover that this meant P = 0.04 (hint -it’s 6 lines above Table 1). That means that there is around a 50% chance that it’s a false discovery.
- The test was short -only three months
- The test didn’t measure memory anyway. It measured reaction speed, They did test memory retention too, and there was no detectable improvement. This was not mentioned in the abstract, Neither was the fact that exercise had no detectable effect.
- The study was funded by the Mars bar company. They, like many others, are clearly looking for a niche in the huge "supplement" market,
The claims by the senior author, in a Columbia promotional video that the drink produced "an improvement in memory" and "an improvement in memory performance by two or three decades" seem to have a very thin basis indeed. As has the statement that "we don’t need a pharmaceutical agent" to ameliorate a natural process (aging). High doses of supplements are pharmaceutical agents.
To be fair, the senior author did say, in the Columbia press release, that "the findings need to be replicated in a larger study—which he and his team plan to do". But there is no hint of this in the paper itself, or in the title of the press release "Dietary Flavanols Reverse Age-Related Memory Decline". The time for all the publicity is surely after a well-powered study, not before it.
The high altmetrics score for this paper is yet another blow to the reputation of altmetrics.
One may well ask why Nature Neuroscience and the Columbia press office allowed such extravagant claims to be made on such a flimsy basis.
What’s going wrong?
These two papers have much in common. Elaborate imaging studies are accompanied by poor functional tests. All the hype focusses on the latter. These led me to the speculation ( In Pubmed Commons) that what actually happens is as follows.
- Authors do big imaging (fMRI) study.
- Glamour journal says coloured blobs are no longer enough and refuses to publish without functional information.
- Authors tag on a small human study.
- Paper gets published.
- Hyped up press releases issued that refer mostly to the add on.
- Journal and authors are happy.
- But science is not advanced.
It’s no wonder that Dorothy Bishop wrote "High-impact journals: where newsworthiness trumps methodology".
It’s time we forgot glamour journals. Publish open access on the web with open comments. Post-publication peer review is working
But boycott commercial publishers who charge large amounts for open access. It shouldn’t cost more than about £200, and more and more are essentially free (my latest will appear shortly in Royal Society Open Science).
Hilda Bastian has an excellent post about the dangers of reading only the abstract "Science in the Abstract: Don’t Judge a Study by its Cover"
4 November 2014
I was upbraided on Twitter by Euan Adie, founder of Almetric.com, because I didn’t click through the altmetric symbol to look at the citations "shouldn’t have to tell you to look at the underlying data David" and "you could have saved a lot of Google time". But when I did do that, all I found was a list of media reports and blogs -pretty much the same as Nature Neuroscience provides itself.
More interesting, I found that my blog wasn’t listed and neither was PubMed Commons. When I asked why, I was told "needs to regularly cite primary research. PubMed, PMC or repository links”. But this paper is behind a paywall. So I provide (possibly illegally) a copy of it, so anyone can verify my comments. The result is that altmetric’s dumb algorithms ignore it. In order to get counted you have to provide links that lead nowhere.
So here’s a link to the abstract (only) in Pubmed for the Science paper http://www.ncbi.nlm.nih.gov/pubmed/25170153 and here’s the link for the Nature Neuroscience paper http://www.ncbi.nlm.nih.gov/pubmed/25344629
It seems that altmetrics doesn’t even do the job that it claims to do very efficiently.
It worked. By later in the day, this blog was listed in both Nature‘s metrics section and by altmetrics. com. But comments on Pubmed Commons were still missing, That’s bad because it’s an excellent place for post-publications peer review.
This discussion seemed to be of sufficient general interest that we submitted is as a feature to eLife, because this journal is one of the best steps into the future of scientific publishing. Sadly the features editor thought that " too much of the article is taken up with detailed criticisms of research papers from NEJM and Science that appeared in the altmetrics top 100 for 2013; while many of these criticisms seems valid, the Features section of eLife is not the venue where they should be published". That’s pretty typical of what most journals would say. It is that sort of attitude that stifles criticism, and that is part of the problem. We should be encouraging post-publication peer review, not suppressing it. Luckily, thanks to the web, we are now much less constrained by journal editors than we used to be.
Here it is.
Scientists don’t count: why you should ignore altmetrics and other bibliometric nightmares
David Colquhoun1 and Andrew Plested2
1 University College London, Gower Street, London WC1E 6BT
2 Leibniz-Institut für Molekulare Pharmakologie (FMP) & Cluster of Excellence NeuroCure, Charité Universitätsmedizin,Timoféeff-Ressowsky-Haus, Robert-Rössle-Str. 10, 13125 Berlin Germany.
Jeffrey Beall is librarian at Auraria Library, University of Colorado Denver. Although not a scientist himself, he, more than anyone, has done science a great service by listing the predatory journals that have sprung up in the wake of pressure for open access. In August 2012 he published “Article-Level Metrics: An Ill-Conceived and Meretricious Idea. At first reading that criticism seemed a bit strong. On mature consideration, it understates the potential that bibliometrics, altmetrics especially, have to undermine both science and scientists.
Altmetrics is the latest buzzword in the vocabulary of bibliometricians. It attempts to measure the “impact” of a piece of research by counting the number of times that it’s mentioned in tweets, Facebook pages, blogs, YouTube and news media. That sounds childish, and it is. Twitter is an excellent tool for journalism. It’s good for debunking bad science, and for spreading links, but too brief for serious discussions. It’s rarely useful for real science.
Surveys suggest that the great majority of scientists do not use twitter (7 — 13%). Scientific works get tweeted about mostly because they have titles that contain buzzwords, not because they represent great science.
What and who is Altmetrics for?
The aims of altmetrics are ambiguous to the point of dishonesty; they depend on whether the salesperson is talking to a scientist or to a potential buyer of their wares.
At a meeting in London , an employee of altmetric.com said “we measure online attention surrounding journal articles” “we are not measuring quality …” “this whole altmetrics data service was born as a service for publishers”, “it doesn’t matter if you got 1000 tweets . . .all you need is one blog post that indicates that someone got some value from that paper”.
These ideas sound fairly harmless, but in stark contrast, Jason Priem (an author of the altmetrics manifesto) said one advantage of altmetrics is that it’s fast “Speed: months or weeks, not years: faster evaluations for tenure/hiring”. Although conceivably useful for disseminating preliminary results, such speed isn’t important for serious science (the kind that ought to be considered for tenure) which operates on the timescale of years. Priem also says “researchers must ask if altmetrics really reflect impact” . Even he doesn’t know, yet altmetrics services are being sold to universities, before any evaluation of their usefulness has been done, and universities are buying them. The idea that altmetrics scores could be used for hiring is nothing short of terrifying.
The problem with bibliometrics
The mistake made by all bibliometricians is that they fail to consider the content of papers, because they have no desire to understand research. Bibliometrics are for people who aren’t prepared to take the time (or lack the mental capacity) to evaluate research by reading about it, or in the case of software or databases, by using them. The use of surrogate outcomes in clinical trials is rightly condemned. Bibliometrics are all about surrogate outcomes.
If instead we consider the work described in particular papers that most people agree to be important (or that everyone agrees to be bad), it’s immediately obvious that no publication metrics can measure quality. There are some examples in How to get good science (Colquhoun, 2007). It is shown there that at least one Nobel prize winner failed dismally to fulfil arbitrary biblometric productivity criteria of the sort imposed in some universities (another example is in Is Queen Mary University of London trying to commit scientific suicide?).
Schekman (2013) has said that science
“is disfigured by inappropriate incentives. The prevailing structures of personal reputation and career advancement mean the biggest rewards often follow the flashiest work, not the best.”
Bibliometrics reinforce those inappropriate incentives. A few examples will show that altmetrics are one of the silliest metrics so far proposed.
The altmetrics top 100 for 2103
The superficiality of altmetrics is demonstrated beautifully by the list of the 100 papers with the highest altmetric scores in 2013 For a start, 58 of the 100 were behind paywalls, and so unlikely to have been read except (perhaps) by academics.
The second most popular paper (with the enormous altmetric score of 2230) was published in the New England Journal of Medicine. The title was Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. It was promoted (inaccurately) by the journal with the following tweet:
Many of the 2092 tweets related to this article simply gave the title, but inevitably the theme appealed to diet faddists, with plenty of tweets like the following:
The interpretations of the paper promoted by these tweets were mostly desperately inaccurate. Diet studies are anyway notoriously unreliable. As John Ioannidis has said
"Almost every single nutrient imaginable has peer reviewed publications associating it with almost any outcome."
This sad situation comes about partly because most of the data comes from non-randomised cohort studies that tell you nothing about causality, and also because the effects of diet on health seem to be quite small.
The study in question was a randomized controlled trial, so it should be free of the problems of cohort studies. But very few tweeters showed any sign of having read the paper. When you read it you find that the story isn’t so simple. Many of the problems are pointed out in the online comments that follow the paper. Post-publication peer review really can work, but you have to read the paper. The conclusions are pretty conclusively demolished in the comments, such as:
“I’m surrounded by olive groves here in Australia and love the hand-pressed EVOO [extra virgin olive oil], which I can buy at a local produce market BUT this study shows that I won’t live a minute longer, and it won’t prevent a heart attack.”
We found no tweets that mentioned the finding from the paper that the diets had no detectable effect on myocardial infarction, death from cardiovascular causes, or death from any cause. The only difference was in the number of people who had strokes, and that showed a very unimpressive P = 0.04.
Neither did we see any tweets that mentioned the truly impressive list of conflicts of interest of the authors, which ran to an astonishing 419 words.
“Dr. Estruch reports serving on the board of and receiving lecture fees from the Research Foundation on Wine and Nutrition (FIVIN); serving on the boards of the Beer and Health Foundation and the European Foundation for Alcohol Research (ERAB); receiving lecture fees from Cerveceros de España and Sanofi-Aventis; and receiving grant support through his institution from Novartis. Dr. Ros reports serving on the board of and receiving travel support, as well as grant support through his institution, from the California Walnut Commission; serving on the board of the Flora Foundation (Unilever). . . “
And so on, for another 328 words.
The interesting question is how such a paper came to be published in the hugely prestigious New England Journal of Medicine. That it happened is yet another reason to distrust impact factors. It seems to be another sign that glamour journals are more concerned with trendiness than quality.
One sign of that is the fact that the journal’s own tweet misrepresented the work. The irresponsible spin in this initial tweet from the journal started the ball rolling, and after this point, the content of the paper itself became irrelevant. The altmetrics score is utterly disconnected from the science reported in the paper: it more closely reflects wishful thinking and confirmation bias.
The fourth paper in the altmetrics top 100 is an equally instructive example.
This work was also published in a glamour journal, Science. The paper claimed that a function of sleep was to “clear metabolic waste from the brain”. It was initially promoted (inaccurately) on Twitter by the publisher of Science.
After that, the paper was retweeted many times, presumably because everybody sleeps, and perhaps because the title hinted at the trendy, but fraudulent, idea of “detox”. Many tweets were variants of “The garbage truck that clears metabolic waste from the brain works best when you’re asleep”.
But this paper was hidden behind Science’s paywall. It’s bordering on irresponsible for journals to promote on social media papers that can’t be read freely. It’s unlikely that anyone outside academia had read it, and therefore few of the tweeters had any idea of the actual content, or the way the research was done. Nevertheless it got “1,479 tweets from 1,355 accounts with an upper bound of 1,110,974 combined followers”. It had the huge Altmetrics score of 1848, the highest altmetric score in October 2013.
Within a couple of days, the story fell out of the news cycle. It was not a bad paper, but neither was it a huge breakthrough. It didn’t show that naturally-produced metabolites were cleared more quickly, just that injected substances were cleared faster when the mice were asleep or anaesthetised. This finding might or might not have physiological consequences for mice.
Worse, the paper also claimed that “Administration of adrenergic antagonists induced an increase in CSF tracer influx, resulting in rates of CSF tracer influx that were more comparable with influx observed during sleep or anesthesia than in the awake state”. Simply put, giving the sleeping mice a drug could reduce the clearance to wakeful levels. But nobody seemed to notice the absurd concentrations of antagonists that were used in these experiments: “adrenergic receptor antagonists (prazosin, atipamezole, and propranolol, each 2 mM) were then slowly infused via the cisterna magna cannula for 15 min”. Use of such high concentrations is asking for non-specific effects. The binding constant (concentration to occupy half the receptors) for prazosin is less than 1 nM, so infusing 2 mM is working at a million times greater than the concentration that should be effective. That’s asking for non-specific effects. Most drugs at this sort of concentration have local anaesthetic effects, so perhaps it isn’t surprising that the effects resembled those of ketamine.
The altmetrics editor hadn’t noticed the problems and none of them featured in the online buzz. That’s partly because to find it out you had to read the paper (the antagonist concentrations were hidden in the legend of Figure 4), and partly because you needed to know the binding constant for prazosin to see this warning sign.
The lesson, as usual, is that if you want to know about the quality of a paper, you have to read it. Commenting on a paper without knowing anything of its content is liable to make you look like an jackass.
A tale of two papers
Another approach that looks at individual papers is to compare some of one’s own papers. Sadly, UCL shows altmetric scores on each of your own papers. Mostly they are question marks, because nothing published before 2011 is scored. But two recent papers make an interesting contrast. One is from DC’s side interest in quackery, one was real science. The former has an altmetric score of 169, the latter has an altmetric score of 2.
The first paper was “Acupuncture is a theatrical placebo”, which was published as an invited editorial in Anesthesia and Analgesia [download pdf]. The paper was scientifically trivial. It took perhaps a week to write.
Nevertheless, it got promoted it on twitter, because anything to do with alternative medicine is interesting to the public. It got quite a lot of retweets. And the resulting altmetric score of 169 put it in the top 1% of all articles altmetric have tracked, and the second highest ever for Anesthesia and Analgesia.
As well as the journal’s own website, the article was also posted on the DCScience.net blog (May 30, 2013) where it soon became the most viewed page ever (24,468 views as of 23 November 2013), something that altmetrics does not seem to take into account.
Compare this with the fate of some real, but rather technical, science.
My [DC] best scientific papers are too old (i.e. before 2011) to have an altmetrics score, but my best score for any scientific paper is 2. This score was for Colquhoun & Lape (2012) “Allosteric coupling in ligand-gated ion channels”. It was a commentary with some original material.
The altmetric score was based on two tweets and 15 readers on Mendeley. The two tweets consisted of one from me (“Real science; The meaning of allosteric conformation changes http://t.co/zZeNtLdU ”).
The only other tweet as abusive one from a cyberstalker who was upset at having been refused a job years ago. Incredibly, this modest achievement got it rated “Good compared to other articles of the same age (71st percentile)”.
Conclusions about bibliometrics
Bibliometricians spend much time correlating one surrogate outcome with another, from which they learn little. What they don’t do is take the time to examine individual papers. Doing that makes it obvious that most metrics, and especially altmetrics, are indeed an ill-conceived and meretricious idea. Universities should know better than to subscribe to them.
Although altmetrics may be the silliest bibliometric idea yet, much this criticism applies equally to all such metrics. Even the most plausible metric, counting citations, is easily shown to be nonsense by simply considering individual papers. All you have to do is choose some papers that are universally agreed to be good, and some that are bad, and see how metrics fail to distinguish between them. This is something that bibliometricians fail to do (perhaps because they don’t know enough science to tell which is which). Some examples are given by Colquhoun (2007) (more complete version at dcscience.net).
Eugene Garfield, who started the metrics mania with the journal impact factor (JIF), was clear that it was not suitable as a measure of the worth of individuals. He has been ignored and the JIF has come to dominate the lives of researchers, despite decades of evidence of the harm it does (e.g.Seglen (1997) and Colquhoun (2003) ) In the wake of JIF, young, bright people have been encouraged to develop yet more spurious metrics (of which ‘altmetrics’ is the latest). It doesn’t matter much whether these metrics are based on nonsense (like counting hashtags) or rely on counting links or comments on a journal website. They won’t (and can’t) indicate what is important about a piece of research- its quality.
People say – I can’t be a polymath. Well, then don’t try to be. You don’t have to have an opinion on things that you don’t understand. The number of people who really do have to have an overview, of the kind that altmetrics might purport to give, those who have to make funding decisions about work that they are not intimately familiar with, is quite small. Chances are, you are not one of them. We review plenty of papers and grants. But it’s not credible to accept assignments outside of your field, and then rely on metrics to assess the quality of the scientific work or the proposal.
It’s perfectly reasonable to give credit for all forms of research outputs, not only papers. That doesn’t need metrics. It’s nonsense to suggest that altmetrics are needed because research outputs are not already valued in grant and job applications. If you write a grant for almost any agency, you can put your CV. If you have a non-publication based output, you can always include it. Metrics are not needed. If you write software, get the numbers of downloads. Software normally garners citations anyway if it’s of any use to the greater community.
When AP recently wrote a criticism of Heather Piwowar’s altmetrics note in Nature, one correspondent wrote: "I haven’t read the piece [by HP] but I’m sure you are mischaracterising it". This attitude summarizes the too-long-didn’t-read (TLDR) culture that is increasingly becoming accepted amongst scientists, and which the comparisons above show is a central component of altmetrics.
Altmetrics are numbers generated by people who don’t understand research, for people who don’t understand research. People who read papers and understand research just don’t need them and should shun them.
But all bibliometrics give cause for concern, beyond their lack of utility. They do active harm to science. They encourage “gaming” (a euphemism for cheating). They encourage short-term eye-catching research of questionable quality and reproducibility. They encourage guest authorships: that is, they encourage people to claim credit for work which isn’t theirs. At worst, they encourage fraud.
No doubt metrics have played some part in the crisis of irreproducibility that has engulfed some fields, particularly experimental psychology, genomics and cancer research. Underpowered studies with a high false-positive rate may get you promoted, but tend to mislead both other scientists and the public (who in general pay for the work). The waste of public money that must result from following up badly done work that can’t be reproduced but that was published for the sake of “getting something out” has not been quantified, but must be considered to the detriment of bibliometrics, and sadly overcomes any advantages from rapid dissemination. Yet universities continue to pay publishers to provide these measures, which do nothing but harm. And the general public has noticed.
It’s now eight years since the New York Times brought to the attention of the public that some scientists engage in puffery, cheating and even fraud.
Overblown press releases written by journals, with connivance of university PR wonks and with the connivance of the authors, sometimes go viral on social media (and so score well on altmetrics). Yet another example, from Journal of the American Medical Association involved an overblown press release from the Journal about a trial that allegedly showed a benefit of high doses of Vitamin E for Alzheimer’s disease.
This sort of puffery harms patients and harms science itself.
We can’t go on like this.
What should be done?
Post publication peer review is now happening, in comments on published papers and through sites like PubPeer, where it is already clear that anonymous peer review can work really well. New journals like eLife have open comments after each paper, though authors do not seem to have yet got into the habit of using them constructively. They will.
It’s very obvious that too many papers are being published, and that anything, however bad, can be published in a journal that claims to be peer reviewed . To a large extent this is just another example of the harm done to science by metrics –the publish or perish culture.
Attempts to regulate science by setting “productivity targets” is doomed to do as much harm to science as it has in the National Health Service in the UK. This has been known to economists for a long time, under the name of Goodhart’s law.
Here are some ideas about how we could restore the confidence of both scientists and of the public in the integrity of published work.
- Nature, Science, and other vanity journals should become news magazines only. Their glamour value distorts science and encourages dishonesty.
- Print journals are overpriced and outdated. They are no longer needed. Publishing on the web is cheap, and it allows open access and post-publication peer review. Every paper should be followed by an open comments section, with anonymity allowed. The old publishers should go the same way as the handloom weavers. Their time has passed.
- Web publication allows proper explanation of methods, without the page, word and figure limits that distort papers in vanity journals. This would also make it very easy to publish negative work, thus reducing publication bias, a major problem (not least for clinical trials)
- Publish or perish has proved counterproductive. It seems just as likely that better science will result without any performance management at all. All that’s needed is peer review of grant applications.
- Providing more small grants rather than fewer big ones should help to reduce the pressure to publish which distorts the literature. The ‘celebrity scientist’, running a huge group funded by giant grants has not worked well. It’s led to poor mentoring, and, at worst, fraud. Of course huge groups sometimes produce good work, but too often at the price of exploitation of junior scientists
- There is a good case for limiting the number of original papers that an individual can publish per year, and/or total funding. Fewer but more complete and considered papers would benefit everyone, and counteract the flood of literature that has led to superficiality.
- Everyone should read, learn and inwardly digest Peter Lawrence’s The Mismeasurement of Science.
A focus on speed and brevity (cited as major advantages of altmetrics) will help no-one in the end. And a focus on creating and curating new metrics will simply skew science in yet another unsatisfactory way, and rob scientists of the time they need to do their real job: generate new knowledge.
It has been said
“Creation is sloppy; discovery is messy; exploration is dangerous. What’s a manager to do?
The answer in general is to encourage curiosity and accept failure. Lots of failure.”
And, one might add, forget metrics. All of them.
17 Jan 2014
This piece was noticed by the Economist. Their ‘Writing worth reading‘ section said
"Why you should ignore altmetrics (David Colquhoun) Altmetrics attempt to rank scientific papers by their popularity on social media. David Colquohoun [sic] argues that they are “for people who aren’t prepared to take the time (or lack the mental capacity) to evaluate research by reading about it.”"
20 January 2014.
Jason Priem, of ImpactStory, has responded to this article on his own blog. In Altmetrics: A Bibliographic Nightmare? he seems to back off a lot from his earlier claim (cited above) that altmetrics are useful for making decisions about hiring or tenure. Our response is on his blog.
20 January 2014.
Jason Priem, of ImpactStory, has responded to this article on his own blog, In Altmetrics: A bibliographic Nightmare? he seems to back off a lot from his earlier claim (cited above) that altmetrics are useful for making decisions about hiring or tenure. Our response is on his blog.
23 January 2014
The Scholarly Kitchen blog carried another paean to metrics, A vigorous discussion followed. The general line that I’ve followed in this discussion, and those mentioned below, is that bibliometricians won’t qualify as scientists until they test their methods, i.e. show that they predict something useful. In order to do that, they’ll have to consider individual papers (as we do above). At present, articles by bibliometricians consist largely of hubris, with little emphasis on the potential to cause corruption. They remind me of articles by homeopaths: their aim is to sell a product (sometimes for cash, but mainly to promote the authors’ usefulness).
It’s noticeable that all of the pro-metrics articles cited here have been written by bibliometricians. None have been written by scientists.
28 January 2014.
Dalmeet Singh Chawla,a bibliometrician from Imperial College London, wrote a blog on the topic. (Imperial, at least in its Medicine department, is notorious for abuse of metrics.)
29 January 2014 Arran Frood wrote a sensible article about the metrics row in Euroscientist.
2 February 2014 Paul Groth (a co-author of the Altmetrics Manifesto) posted more hubristic stuff about altmetrics on Slideshare. A vigorous discussion followed.
5 May 2014. Another vigorous discussion on ImpactStory blog, this time with Stacy Konkiel. She’s another non-scientist trying to tell scientists what to do. The evidence that she produced for the usefulness of altmetrics seemed pathetic to me.
7 May 2014 A much-shortened version of this post appeared in the British Medical Journal (BMJ blogs)